Zacks: Analysts Expect Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Will Announce Earnings of $3.75 Per Share

Brokerages expect Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) to announce earnings of $3.75 per share for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Jazz Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $3.32 and the highest estimate coming in at $4.35. Jazz Pharmaceuticals reported earnings of $3.92 per share in the same quarter last year, which indicates a negative year over year growth rate of 4.3%. The business is scheduled to issue its next earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Jazz Pharmaceuticals will report full-year earnings of $16.51 per share for the current financial year, with EPS estimates ranging from $16.08 to $17.31. For the next year, analysts forecast that the company will post earnings of $17.97 per share, with EPS estimates ranging from $15.00 to $22.16. Zacks’ EPS averages are an average based on a survey of analysts that cover Jazz Pharmaceuticals.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last issued its earnings results on Tuesday, March 1st. The specialty pharmaceutical company reported $3.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.68. The business had revenue of $896.73 million for the quarter, compared to analyst estimates of $866.71 million. Jazz Pharmaceuticals had a negative net margin of 10.65% and a positive return on equity of 21.56%. The company’s revenue for the quarter was up 34.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.56 EPS.

A number of equities research analysts have recently issued reports on JAZZ shares. Piper Sandler cut their target price on shares of Jazz Pharmaceuticals from $209.00 to $197.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 2nd. The Goldman Sachs Group lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $202.00 to $196.00 in a research note on Wednesday, April 6th. HC Wainwright increased their price objective on shares of Jazz Pharmaceuticals from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Thursday, March 3rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $215.00 price objective on shares of Jazz Pharmaceuticals in a research note on Monday, February 7th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $203.92.

In other news, CEO Bruce C. Cozadd sold 10,772 shares of the stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $158.33, for a total value of $1,705,530.76. Following the completion of the transaction, the chief executive officer now directly owns 346,062 shares in the company, valued at $54,791,996.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 6,372 shares of the stock in a transaction that occurred on Tuesday, February 1st. The shares were sold at an average price of $139.23, for a total transaction of $887,173.56. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the company. Gateway Investment Advisers LLC lifted its position in Jazz Pharmaceuticals by 0.4% in the 1st quarter. Gateway Investment Advisers LLC now owns 15,277 shares of the specialty pharmaceutical company’s stock worth $2,378,000 after buying an additional 64 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in Jazz Pharmaceuticals by 1.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 5,746 shares of the specialty pharmaceutical company’s stock worth $748,000 after buying an additional 81 shares in the last quarter. CWM LLC raised its holdings in shares of Jazz Pharmaceuticals by 25.2% during the 1st quarter. CWM LLC now owns 422 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 85 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 3.0% during the 3rd quarter. Daiwa Securities Group Inc. now owns 3,106 shares of the specialty pharmaceutical company’s stock valued at $404,000 after purchasing an additional 90 shares in the last quarter. Finally, Securian Asset Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 1.8% during the 4th quarter. Securian Asset Management Inc. now owns 5,523 shares of the specialty pharmaceutical company’s stock valued at $704,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 91.95% of the company’s stock.

Shares of Jazz Pharmaceuticals stock traded down $0.97 during trading on Friday, reaching $160.22. The company had a trading volume of 539,134 shares, compared to its average volume of 507,641. The company has a market cap of $9.89 billion, a price-to-earnings ratio of -29.40, a price-to-earnings-growth ratio of 1.40 and a beta of 0.87. The firm’s fifty day moving average is $157.05 and its 200-day moving average is $142.18. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.90 and a current ratio of 3.23. Jazz Pharmaceuticals has a fifty-two week low of $117.64 and a fifty-two week high of $189.00.

Jazz Pharmaceuticals Company Profile (Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Recommended Stories